Nrf2-Independent Anti-Inflammatory Effects of Dimethyl Fumarate: Challenges and Prospects in Developing Electrophilic Nrf2 Activators for Neurodegenerative Diseases

Overview

Journal Antioxidants (Basel)

Date 2025 Jan 8

PMID 39765855

Authors

Yasuhiko Izumi

Yutaka Koyama

Affiliations

Soon will be listed here.

Abstract

The NF-E2-related factor 2 (Nrf2)-antioxidant response element (ARE) pathway is a potential therapeutic target for central nervous system diseases. This review emphasizes the role of oxidative stress and neuroinflammation in neurodegenerative diseases, highlighting the therapeutic potential of Nrf2 activators such as dimethyl fumarate (DMF). DMF, initially administered for treating psoriasis, has demonstrated efficacy in multiple sclerosis and is metabolized to monomethyl fumarate, which may exert significant therapeutic effects. DMF activates the Nrf2-ARE pathway, and recent studies have indicated that its anti-inflammatory effects occur through Nrf2-independent mechanisms. Electrophilic Nrf2 activators, such as DMF, covalently bind to cysteine residues in proteins and modulate their function. We discuss the implications of cysteine residue modifications by DMF, which may cause both therapeutic benefits and potential off-target effects. Furthermore, we propose a chemical proteomics-based drug discovery approach to achieve desired therapeutic effects by selectively covalently modifying cysteines in target proteins. These findings advocate for a broader understanding of the Nrf2-independent mechanisms of electrophilic Nrf2 activators, thereby improving drug discovery strategies that target neurodegenerative diseases while minimizing toxicity.

References

Piroli G, Manuel A, Patel T, Walla M, Shi L, Lanci S . Identification of Novel Protein Targets of Dimethyl Fumarate Modification in Neurons and Astrocytes Reveals Actions Independent of Nrf2 Stabilization. Mol Cell Proteomics. 2018; 18(3):504-519. PMC: 6398201. DOI: 10.1074/mcp.RA118.000922. View

von Glehn F, Dias-Carneiro R, Moraes A, Farias A, Silva V, Oliveira F . Dimethyl fumarate downregulates the immune response through the HCA/GPR109A pathway: Implications for the treatment of multiple sclerosis. Mult Scler Relat Disord. 2018; 23:46-50. DOI: 10.1016/j.msard.2018.04.016. View

Tran K, Pallesen J, Solbak S, Narayanan D, Baig A, Zang J . A Comparative Assessment Study of Known Small-Molecule Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity. J Med Chem. 2019; 62(17):8028-8052. DOI: 10.1021/acs.jmedchem.9b00723. View

McAulay K, Bilsland A, Bon M . Reactivity of Covalent Fragments and Their Role in Fragment Based Drug Discovery. Pharmaceuticals (Basel). 2022; 15(11). PMC: 9694498. DOI: 10.3390/ph15111366. View

Peng H, Guerau-de-Arellano M, Mehta V, Yang Y, Huss D, Papenfuss T . Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. J Biol Chem. 2012; 287(33):28017-26. PMC: 3431702. DOI: 10.1074/jbc.M112.383380. View

Johnson D, Amirahmadi S, Ward C, Fabry Z, Johnson J . The absence of the pro-antioxidant transcription factor Nrf2 exacerbates experimental autoimmune encephalomyelitis. Toxicol Sci. 2009; 114(2):237-46. PMC: 2902921. DOI: 10.1093/toxsci/kfp274. View

Chen H, Assmann J, Krenz A, Rahman M, Grimm M, Karsten C . Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE. J Clin Invest. 2014; 124(5):2188-92. PMC: 4001545. DOI: 10.1172/JCI72151. View

Johnson D, Johnson J . Nrf2--a therapeutic target for the treatment of neurodegenerative diseases. Free Radic Biol Med. 2015; 88(Pt B):253-267. PMC: 4809057. DOI: 10.1016/j.freeradbiomed.2015.07.147. View

Bond L, Bernhardt K, Madria P, Sorrentino K, Scelsi H, Mitchell C . A Metadata Analysis of Oxidative Stress Etiology in Preclinical Amyotrophic Lateral Sclerosis: Benefits of Antioxidant Therapy. Front Neurosci. 2018; 12:10. PMC: 5787557. DOI: 10.3389/fnins.2018.00010. View

10.

Petrillo S, Piermarini E, Pastore A, Vasco G, Schirinzi T, Carrozzo R . Nrf2-Inducers Counteract Neurodegeneration in Frataxin-Silenced Motor Neurons: Disclosing New Therapeutic Targets for Friedreich's Ataxia. Int J Mol Sci. 2017; 18(10). PMC: 5666854. DOI: 10.3390/ijms18102173. View

11.

Hong F, Freeman M, Liebler D . Identification of sensor cysteines in human Keap1 modified by the cancer chemopreventive agent sulforaphane. Chem Res Toxicol. 2005; 18(12):1917-26. DOI: 10.1021/tx0502138. View

12.

Gold R, Kappos L, Arnold D, Bar-Or A, Giovannoni G, Selmaj K . Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012; 367(12):1098-107. DOI: 10.1056/NEJMoa1114287. View

13.

Majkutewicz I . Dimethyl fumarate: A review of preclinical efficacy in models of neurodegenerative diseases. Eur J Pharmacol. 2022; 926:175025. DOI: 10.1016/j.ejphar.2022.175025. View

14.

Hu C, Eggler A, Mesecar A, van Breemen R . Modification of keap1 cysteine residues by sulforaphane. Chem Res Toxicol. 2011; 24(4):515-21. PMC: 3086360. DOI: 10.1021/tx100389r. View

15.

Zaro B, Vinogradova E, Lazar D, Blewett M, Suciu R, Takaya J . Dimethyl Fumarate Disrupts Human Innate Immune Signaling by Targeting the IRAK4-MyD88 Complex. J Immunol. 2019; 202(9):2737-2746. PMC: 6478521. DOI: 10.4049/jimmunol.1801627. View

16.

Sarlette A, Krampfl K, Grothe C, von Neuhoff N, Dengler R, Petri S . Nuclear erythroid 2-related factor 2-antioxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2008; 67(11):1055-62. DOI: 10.1097/NEN.0b013e31818b4906. View

17.

Schulze-Topphoff U, Varrin-Doyer M, Pekarek K, Spencer C, Shetty A, Sagan S . Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. Proc Natl Acad Sci U S A. 2016; 113(17):4777-82. PMC: 4855599. DOI: 10.1073/pnas.1603907113. View

18.

Gillard G, Collette B, Anderson J, Chao J, Scannevin R, Huss D . DMF, but not other fumarates, inhibits NF-κB activity in vitro in an Nrf2-independent manner. J Neuroimmunol. 2015; 283:74-85. DOI: 10.1016/j.jneuroim.2015.04.006. View

19.

Blewett M, Xie J, Zaro B, Backus K, Altman A, Teijaro J . Chemical proteomic map of dimethyl fumarate-sensitive cysteines in primary human T cells. Sci Signal. 2016; 9(445):rs10. PMC: 5068918. DOI: 10.1126/scisignal.aaf7694. View

20.

Tannahill G, Curtis A, Adamik J, Palsson-McDermott E, McGettrick A, Goel G . Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature. 2013; 496(7444):238-42. PMC: 4031686. DOI: 10.1038/nature11986. View